Key result
Atrasentan (0.75 mg and 1.75 mg) significantly reduced urine albumin-to-creatinine ratio by 42% and 35% versus placebo over 8 weeks in patients with type 2 diabetes and CKD (P<0.011).
Why the study?
Does atrasentan reduce UACR in patients with type 2 diabetes and CKD on RAS inhibitors?
RCT
Double-blind
randomized
Does atrasentan reduce UACR in patients with type 2 diabetes and CKD on RAS inhibitors?
Effect estimate: 42% and 35% reduction vs placebo
p-value: p=<0.011
Atrasentan significantly reduces albuminuria when added to RAS inhibitors in patients with type 2 diabetes and CKD, though it is associated with early edema formation.
No takes yet. Share an insight, caveat, or question.
Supports atrasentan addition to RAS inhibitors for albuminuria reduction in T2D-CKD; extends endothelin antagonism evidence in diabetic nephropathy.
Andress et al. (2012) conducted an RCT in Type 2 diabetes and chronic kidney disease. Atrasentan vs. Placebo was evaluated on Urine albumin-to-creatinine ratio (UACR) reduction (42% and 35% reduction vs placebo, p=<0.011). Atrasentan (0.75 mg and 1.75 mg) significantly reduced urine albumin-to-creatinine ratio by 42% and 35% versus placebo over 8 weeks in patients with type 2 diabetes and CKD (P<0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: